Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded
- Contract number
- SPE2DB25FZX13
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,488
Award facts
- Contract value 100% obligated
- $18,488.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, awarded on June 4, 2025, with an ultimate completion date of June 5, 2025, was issued without a set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities nationwide.
DMS Pharmaceutical Group has established itself as a key supplier in the federal pharmaceutical supply chain through its robust portfolio of delivery orders from the Defense Logistics Agency, specializing in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. The company's contract history demonstrates consistent success in securing federal pharmaceutical procurement opportunities, leveraging its woman-owned small business status to compete effectively in the marketplace. Trikafta, a cystic fibrosis treatment, represents the type of specialized pharmaceutical product that the company regularly delivers to support military health operations.
Quick answers
Who was awarded contract SPE2DB25FZX13?
SPE2DB25FZX13 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 4, 2025.
How much is contract SPE2DB25FZX13 worth?
The government has obligated $18,488 on SPE2DB25FZX13.
Is contract SPE2DB25FZX13 an order under another contract?
Yes. SPE2DB25FZX13 is a delivery order under SPE2DB20D9135, an indefinite delivery contract.
Was contract SPE2DB25FZX13 competed?
The extent of competition for SPE2DB25FZX13 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award